Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Sigma-Aldrich Launches Services Network

By Drug Discovery Trends Editor | June 10, 2009

Sigma-Aldrich launched their Services Network designed to provide laboratory services for the pharmaceutical and biotechnology industry. The Services Network provides researchers with access to a wide variety of laboratory-based services from a centralized website location. The Network will allow scientists to engage Sigma-Aldrich resources and certified partners for laboratory services on an as-needed basis, freeing them to concentrate on core research objectives.

With this, scientists from the pharmaceutical and biotechnology industry can select from a menu of laboratory services, including cloning, mass spectrometry based protein characterization, protein expression and protein purification services to supplement their research and support drug discovery. The Services Network includes Sigma-Aldrich’s core capabilities and numerous Sigma Certified partners located in the United States as well as from emergent locales. Additional certified partners are expected to be added in the future, expanding the services menu.

“The Sigma-Aldrich Services Network offers a powerful tool that addresses an expanding demand for services to support advanced life science research. While many companies may offer individual services, our global network offers an expanding variety of services, complements our product portfolio and comes with the single-source convenience and the proven reliability of Sigma-Aldrich,” said Helge Bastian, Vice President of Marketing and Business Development at Sigma-Aldrich.

Date: June 9, 2009
Source: Sigma-Aldrich 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50